|
ORF cDNA clones
|
CRISPR / TALEN
|
Lentivirus
|
AAV
|
TALE-TF
|
ORF knockin clones
|
|
Antibody
|
Proteins
|
miRNA target clones
|
qPCR primers
|
shRNA clones
|
miRNA products
|
Promoter clones
|
Validated All-in-One™ qPCR Primer for SLC7A5(NM_003486.7) Search again
Product ID:
HQP127393
(click here to view gene annotation page)
Powered by BiozSpecies:
Human
Symbol:
Alias:
4F2LC, CD98, D16S469E, E16, LAT1, MPE16
Gene Description:
solute carrier family 7 member 5
Target Gene Accession:
NM_003486.7(click here to view gene page)
Estimated Delivery:
Approximately 1-3 weeks, but may vary. Please email sales@genecopoeia.com or call 301-762-0888 to confirm ETA.
Important Note:
By default, qPCR primer pairs are designed to measure the expression level of the splice variant (accession number) you selected for this gene WITHOUT consideration of other possible variants of this gene. If this gene has multiple variants, and you would like to measure the expression levels of one particular variant, multiple variants, or all variants, please contact us for a custom service project at inquiry@genecopoeia.com.
Gene References into function
- study indicates the functional interaction between CD98 and CD147 in the regulation of cell fusion
- Increased LAT1 expression can be induced by lipid oxidation products relevant to inflammatory responses in atherogenesis. LAT1 mediates lysophosphatidylcholine-enhanced cytokine production by endothelial cells.
- Differences in L-DOPA handling between SHR and WKY cells may result from over-expression of LAT1 and LAT2 transporters in the former.
- studies demonstrate that the only known SNP in the open reading frame of human LAT1 has no effect on the kinetics of large neutral amino acid transport via this carrier
- identify LAT1 and LAT2 as members of system L that mediate transmembrane movement of l-CSNO
- In vivo efforts focusing on LAT1/CD98 as a potential therapeutic target in liver cells.
- LAT1 expression may increase with the upregulation of metabolic activity and cell proliferation in high-grade atypical adenomatous hyperplasia and bronchioloalveolar carcinoma.
- Findings suggest that LAT1 could be one of the molecular targets in glioma therapy.
- Genetic variation in LAT1 and LAT2 does not appear to be a major cause of inter-individual variability in pharmacokinetics and of adverse reactions to melphalan.
- expression of LAT1 protein and mRNA in 124 cases of transitional cell carcinoma of the upper urinary tract was examined; detection of the active form LAT1 protein appears to be of value in informing the risk of progression
- Overexpression of L-type amino acid transporter 1 is associated with nonsmall cell lung cancer
- This study demonstrated that LAT1 is involved in 90% of total uptake of tyrosine and also around 51% of alanine. Not more than 10% can be accounted for by LAT2, LAT3 and LAT4 isoforms.
- Comparative immunohistochemical analyses of normal human tissues with anti-CD98 hc and anti-LAT1 revealed LAT1 to be an excellent molecular target for antibody therapy, possibly even superior to CD98 hc.
- LAT1 may play an important role in enhancing the rates of tumor cell proliferation and growth in vivo.
- Expression of LAT1 tended to increase from low-grade to high-grade neuroendocrine tumors.
- Inhibition of system L (LAT1/CD98hc) reduces the growth of cultured human breast cancer cells.
- LAT1 expression in primary and metastatic neoplasms is reported.
- elevated LAT1 expression in prostate cancers is a novel independent biomarker of high-grade malignancy